- Home
- PHAR vs WLKP Comparison
PHAR vs WLKP Comparison
Compare PHAR & WLKP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PHAR
- WLKP
- Stock Information
- Founded
- PHAR 1988
- WLKP 2014
- Country
- PHAR Netherlands
- WLKP United States
- Employees
- PHAR N/A
- WLKP N/A
- Industry
- PHAR Biotechnology: Pharmaceutical Preparations
- WLKP Major Chemicals
- Sector
- PHAR Health Care
- WLKP Industrials
- Exchange
- PHAR Nasdaq
- WLKP Nasdaq
- Market Cap
- PHAR 731.1M
- WLKP 789.3M
- IPO Year
- PHAR N/A
- WLKP 2014
- Fundamental
- Price
- PHAR $10.00
- WLKP $22.38
- Analyst Decision
- PHAR Strong Buy
- WLKP
- Analyst Count
- PHAR 3
- WLKP 0
- Target Price
- PHAR $30.00
- WLKP N/A
- AVG Volume (30 Days)
- PHAR 3.6K
- WLKP 31.8K
- Earning Date
- PHAR 07-31-2025
- WLKP 08-05-2025
- Dividend Yield
- PHAR N/A
- WLKP 8.37%
- EPS Growth
- PHAR N/A
- WLKP N/A
- EPS
- PHAR N/A
- WLKP 1.49
- Revenue
- PHAR $320,708,000.00
- WLKP $1,088,852,000.00
- Revenue This Year
- PHAR $13.31
- WLKP $8.90
- Revenue Next Year
- PHAR $7.68
- WLKP $6.87
- P/E Ratio
- PHAR N/A
- WLKP $15.06
- Revenue Growth
- PHAR 24.13
- WLKP N/A
- 52 Week Low
- PHAR $6.65
- WLKP $21.19
- 52 Week High
- PHAR $12.61
- WLKP $25.04
- Technical
- Relative Strength Index (RSI)
- PHAR 43.61
- WLKP 51.53
- Support Level
- PHAR $9.99
- WLKP $22.22
- Resistance Level
- PHAR $10.59
- WLKP $22.60
- Average True Range (ATR)
- PHAR 0.35
- WLKP 0.29
- MACD
- PHAR -0.14
- WLKP 0.06
- Stochastic Oscillator
- PHAR 7.45
- WLKP 70.00
About PHAR Pharming Group N.V.
Pharming Group is a biopharmaceutical company focused in transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company is actively developing and commercializing a diverse portfolio of innovative treatments, including both biologics and small molecule therapies. Its commercial products are RUCONEST, approved for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema, or HAE; and Joenja (leniolisib), a small-molecule kinase inhibitor, developed for the treatment of activated phosphoinositide 3-kinase delta syndrome.
About WLKP Westlake Chemical Partners LP Common Units representing limited partner interests
Westlake Chemical Partners LP is a part of the chemical industry in the United States. Its operations are conducted through OpCo, it acquires and develops ethylene production facilities, which convert ethane into ethylene. OpCo sells ethylene and its co-products such as propylene, crude butadiene, pyrolysis gasoline, and hydrogen to Westlake and other customers located in the United States. Its assets include three ethylene production facilities in Calvert City, Kentucky, and Lake Charles, Louisiana.